马蔺子素在抗肿瘤方面的研究现状  

Research status of irisquinone in antitumor therapy

作　　者：李雅静[1] 张富赓[2] LI Ya- jing ZHANG Fu- geng(Department of Pharmacy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin＇s Clinical Research Center for Cancer, Tianjin 300050, China Department of Pharmacy, Tianfin Huanhu Hospital, Tianfin 300060, China)

机构地区：[1]天津医科大学肿瘤医院药学部,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心,天津300060 [2]天津市环湖医院药剂科,天津300350

出　　处：《中国临床药理学杂志》2017年第8期757-759,共3页The Chinese Journal of Clinical Pharmacology

基　　金：天津市卫生局科技基金资助项目(2015KZ051)

摘　　要：马蔺子素是从马蔺子中提取的醌类化合物,其具有高效低毒等优点,对肺癌、头颈癌等有很好的疗效。马蔺子素是针对乏氧细胞的一类放射增敏剂,还能加速病灶的缩小,增加肿瘤全消率,降低肿瘤复发率,提高患者生存率。本文旨在通过对马蔺子素的化学成分及药理作用研究情况的作一综述,为扩大该药的适应证和老药新用提供科学依据。Irisquinone is extracted from marin son quinone compounds, it has the advantages of high efficiency low toxicity, such as lung cancer, head and neck cancer has good curative effect. Irisqninone is in view of the lack of oxygen to cells of radiotherapy sensitization agent, can also accelerate the lesions of narrow, increase the rate of tumor all disappear, reduce tumor recurrence rate, improve patient surial. This paper aims to research summary of the chemical components and pharmacological effects, to enlarge the indications of the drug, ＂old drugs with new＂ provided the scientific basis.

关 键 词：马蔺子素 肺癌 肿瘤 增敏剂 

分 类 号：R979.1[医药卫生—药品]